Back to News
Market Impact: 0.15
Perspective Therapeutics, Inc. Announces Updated Interim Phase 1/2a Data for [212Pb]Lapemelanotide Zapixetar (VMT01) in Advanced Melanoma
Source: Nasdaq
Healthcare & Biotech
Perspective Therapeutics announced updated interim monotherapy results from its ongoing Phase 1/2a trial of investigational targeted alpha therapy [212Pb]lapemelanotide zapixetar (VMT01). The company presented the data as a poster at the Society for Immunotherapy; the provided article text does not include trial outcomes or numerical results.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
More News
- Apollo-backed dental firm vVardis seeks up to $229 million in US IPO
- Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction
- Jefferies raises Inovio stock price target on regulatory win
- Truist raises Vericel stock price target on MACI growth momentum
- Hims & Hers stock climbs on direct partnership with Eli Lilly for obesity drugs
- IRTC Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into iRhythm Technologies, Inc. (IRTC)
From AllMind Research
- AllMind Platform Feature Updates - Fall 2026
- AI Credit Covenant Monitoring: From Clause to Review
- AI-Led Expert Interviews vs. Transcript Libraries
- Run Cost-Controlled Financial Research in AllMind Agent Studio
- AllMind Discusses Ontario's AI Economy with Minister Stephen Crawford and Supply Ontario CEO James Wallace